Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol.
Brice P, Simon D, Bouabdallah R, Bélanger C, Haïoun C, Thieblemont C, Tilly H, Harousseau JL, Doyen C, Martin C, Brousse N, Solal-Céligny PH; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Brice P, et al. Among authors: thieblemont c. Ann Oncol. 2000 Dec;11(12):1585-90. doi: 10.1023/a:1008399623564. Ann Oncol. 2000. PMID: 11205467 Free article. Clinical Trial.
Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
Thieblemont C, Bouafia F, Hornez E, Dumontet C, Tartas S, Antal D, Lemieux B, Traullé C, Espinouse D, Salles G, Coiffier B. Thieblemont C, et al. Leuk Lymphoma. 2004 Apr;45(4):711-4. doi: 10.1080/10428190310001615675. Leuk Lymphoma. 2004. PMID: 15160944 Clinical Trial.
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Mounier N, Gisselbrecht C, Brière J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Mounier N, et al. Among authors: thieblemont c. Ann Oncol. 2004 Dec;15(12):1790-7. doi: 10.1093/annonc/mdh471. Ann Oncol. 2004. PMID: 15550584 Free article.
Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
Sibon D, Ertault M, Al Nawakil C, de Bazelaire C, Franchi P, Brière J, de Kerviler E, Beranger N, Thieblemont C, Brice P. Sibon D, et al. Among authors: thieblemont c. Br J Haematol. 2011 Apr;153(2):191-8. doi: 10.1111/j.1365-2141.2011.08594.x. Epub 2011 Mar 8. Br J Haematol. 2011. PMID: 21385169 Free article. Clinical Trial.
406 results